Corticotropin-releasing factor (CRF) antagonists having the formulae
1
wherein the dashed lines, A, B, Y, Z, G, R
3
, R
4
, R
5
, R
6
, R
16
and R
17
are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
CRF antagonists of Formulas I-V, wherein the B group in the Formulas contains an oxime.
The variables in the Formulas have the meanings described herein.